Julie Desrosiers is the leader of Fasken Martineau's Global Technology & Intellectual Property group.
Ms. Desrosiers regularly acts on behalf of high technology businesses in connection with injunctions, seizures and procedures seeking to protect elements of their intellectual property or their trade secrets and strategic information. Currently, Ms. Desrosiers’ practice is almost exclusively in IP litigation, primarily in the field of patent litigation with an emphasis on pharmaceutical patents, including major patent infringement cases.
Recent and current cases include: as co-counsel for Lundbeck, won major patent NOC litigation over escitalopram, against 7 generics over 4 years (including 2 appeal wins in the Federal Court of Appeal); lead counsel for Lundbeck in section 8 case over citalopram; lead counsel to Cedrom SNI in three class actions by freelancers claiming $500M for infringement of copyright by electronic reproduction of their work; co-counsel to Eurocopter in a successful patent infringement case concerning an helicopter landing gear; as lead counsel to Lundbeck won Escitalopram patent impeachment action; co-counsel to Duchesnay in ongoing Diclectin NOC litigation against three generics; represented LEO pharma in a NOC proceeding against Teva where the Court confirmed the validity of LEO pharma’s patent; appeared before the Supreme Court of Canada on behalf of FICPI in a major patent litigation concerning the test for the utility of a patent in Canada.
Managing IP writes about her: Julie Desrosiers “has got a real fighting spirit – she can rip apart a case. She focuses incredibly hard on the detail and offers in-depth analysis. She has a deep understanding of chemistry, and can take in very complex questions in this discipline. This is an essential skill, because you need to be able to explain it to a judge who doesn’t understand it at all.”